Sectors
IMMX
Immix Biopharma, Inc.
14.03
2 x 10.03
2 x 17.47
bid
ask
+
0.09
0.65%
2 @ 07:30 PM
14.03 +0.00 (0.00%)
| Ytd | 168.26% | |
| 1y | 531.98% |
13.52
day range
14.15
1.94
52 week range
15.10
| Open | 13.70 | Prev Close | 13.94 | Low | 13.52 | High | 14.15 | Mkt Cap | 998.80M |
| Vol | 1.33M | Avg Vol | 1.83M | EPS | -0.88 | P/E | N/A | Forward P/E | -15.83 |
| Beta | 0.11 | Short Ratio | 6.34 | Inst. Own | 78.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-06 | 50-d Avg | 10.58 | 200-d Avg | 8.26 | 1yr Est | 20.27 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-06 | 2026-09 | -0.18 | N/A | N/A | N/A |
| 2026-08-07 | 2026-06 | -0.17 | -0.18 | -0.01 | -5.88% |
| 2026-05-07 | 2026-03 | -0.21 | -0.18 | 0.03 | 14.29% |
| 2026-03-25 | 2025-12 | -0.21 | -0.27 | -0.06 | -28.57% |
| 2025-11-07 | 2025-09 | -0.19 | -0.24 | -0.05 | -26.32% |
| 2025-08-08 | 2025-06 | -0.21 | -0.22 | -0.01 | -4.76% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-11 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-08-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-22 | Needham | Upgrade | Buy | |
| 2026-06-18 | B of A Securities | Upgrade | Buy | |
| 2026-06-17 | LifeSci Capital | Upgrade | Outperform | |
| 2026-05-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-21 | ADAMS HELEN C | Director | 181.00K | Stock Award(Grant) |
| 2026-05-21 | BUCHAN MELISSA JANE | Director | 28.71K | Stock Award(Grant) |
| 2026-05-21 | CHANG NANCY T | Director | 925.13K | Stock Award(Grant) |
| 2026-05-21 | CHUDNOVSKY YEKATERINA | Director | 3.25M | Stock Award(Grant) |
| 2026-05-21 | HSU JASON | Director | 4.87M | Stock Award(Grant) |
| 2026-05-21 | MARQUET MAGDA | Director | 72.34K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Jupiter Topco LLC | 9.78M | 140.00M | 13.68% |
| 2026-06-29 | Saturn V Capital Management LP | 4.66M | 66.66M | 6.51% |
| 2026-06-29 | Eventide Asset Management LLC | 3.89M | 55.68M | 5.44% |
| 2026-06-29 | State Street Corporation | 3.00M | 42.89M | 4.19% |
| 2026-06-29 | Blackrock Inc. | 2.99M | 42.79M | 4.18% |
| 2026-06-29 | Deep Track Capital, Lp | 2.78M | 39.71M | 3.88% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 2.55M | 36.48M | 3.56% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.10M | 30.00M | 2.93% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.29M | 18.40M | 1.80% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 1.07M | 15.28M | 1.49% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 456.67K | 6.53M | 0.64% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 Growth ETF | 370.70K | 5.30M | 0.52% |